Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds

AIM: Traditionally, early phase clinical trials in oncology have been performed in patients based on safety risk-benefit assessment. Therapeutic transition to immuno-oncology may open new opportunities for studies in healthy volunteers, which are conducted faster and are less susceptible to confound...

Descripción completa

Detalles Bibliográficos
Autores principales: Radanovic, Igor, Klarenbeek, Naomi, Rissmann, Robert, Groeneveld, Geert Jan, van Brummelen, Emilie M. J., Moerland, Matthijs, Bosch, Jacobus J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465458/
https://www.ncbi.nlm.nih.gov/pubmed/36106110
http://dx.doi.org/10.3389/fonc.2022.954806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465458/
https://www.ncbi.nlm.nih.gov/pubmed/36106110
http://dx.doi.org/10.3389/fonc.2022.954806

Ejemplares similares